Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24090135 | 0.91 | USP2 (0.48) | RAB9ASMN1; SMN2PDE7AMAPTUSP2 | |
| SCHEMBL24089990 | 0.88 | IDO1 (0.46) | ALOX12MDM2RAB9ACXCR3 | |
| SCHEMBL24090131 | 0.88 | MAT2A (0.44) | ALOX12MDM2 | |
| SCHEMBL24089986 | 0.87 | ALOX12 (0.55) | ALOX12MDM2RAB9ASMN1; SMN2PDE7A | |
| SCHEMBL24090113 | 0.82 | ALOX12 (0.50) | ALOX12MDM2RAB9ASMN1; SMN2PDE7A | |
| SCHEMBL24090013 | 0.82 | ALDH1A1 (0.48) | RAB9ASMN1; SMN2PDE7AMAPTUSP2 | |
| SCHEMBL24089969 | 0.80 | IDO1 (0.42) | PDE7AMAPTUSP2 | |
| SCHEMBL24110995 | 0.79 | ALOX12 (0.57) | ALOX12MDM2RAB9APDE7AMAPT | |
| SCHEMBL24089946 | 0.79 | ACP1 (0.49) | RAB9APDE7AMAPTUSP2 | |
| SCHEMBL29623228 | 0.79 | ACP1 (0.49) | RAB9APDE7AMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | ALOX12 3008/4885MDM2 4282/4885RAB9A 1045/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | ALOX12 3295/4885MDM2 4138/4885RAB9A 902/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | ALOX12 3295/4885MDM2 4138/4885RAB9A 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.